Login to Your Account



Financings Roundup

CoDa Series B Brings in $19.2M for Venous Leg Ulcer Phase II

By Tom Wall


Tuesday, April 19, 2011
San Diego-based CoDa Therapeutics Inc. raised $19.2 million in a Series B financing, allowing the biotech to a push forward with a large Phase II multicenter venous leg ulcer trial with Nexagon, its lead product for chronic wound patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription